Molecular benchmarks of a SARS-CoV-2 epidemic.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
15 06 2021
Historique:
received: 04 08 2020
accepted: 21 05 2021
entrez: 16 6 2021
pubmed: 17 6 2021
medline: 13 7 2021
Statut: epublish

Résumé

A pressing concern in the SARS-CoV-2 epidemic and other viral outbreaks, is the extent to which the containment measures are halting the viral spread. A straightforward way to assess this is to tally the active cases and the recovered ones throughout the epidemic. Here, we show how epidemic control can be assessed with molecular information during a well characterized epidemic in Iceland. We demonstrate how the viral concentration decreased in those newly diagnosed as the epidemic transitioned from exponential growth phase to containment phase. The viral concentration in the cases identified in population screening decreased faster than in those symptomatic and considered at high risk and that were targeted by the healthcare system. The viral concentration persists in recovering individuals as we found that half of the cases are still positive after two weeks. We demonstrate that accumulation of mutations in SARS-CoV-2 genome can be exploited to track the rate of new viral generations throughout the different phases of the epidemic, where the accumulation of mutations decreases as the transmission rate decreases in the containment phase. Overall, the molecular signatures of SARS-CoV-2 infections contain valuable epidemiological information that can be used to assess the effectiveness of containment measures.

Identifiants

pubmed: 34131116
doi: 10.1038/s41467-021-23883-6
pii: 10.1038/s41467-021-23883-6
pmc: PMC8206085
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3633

Références

Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Commun. 2020 Sep 1;11(1):4376
pubmed: 32873808
Int J Infect Dis. 2006 Jan;10(1):32-7
pubmed: 16023880
Cell. 2020 May 14;181(4):914-921.e10
pubmed: 32330414
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Cell. 2020 May 28;181(5):990-996.e5
pubmed: 32386545
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
N Engl J Med. 2020 Nov 26;383(22):2184-2185
pubmed: 33147384
Mol Biol Evol. 2016 Apr;33(4):863-9
pubmed: 26882983
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Front Microbiol. 2017 Feb 02;8:108
pubmed: 28210243
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243
pubmed: 32269081
Nat Genet. 2017 Nov;49(11):1654-1660
pubmed: 28945251
J Virol. 2018 Jun 29;92(14):
pubmed: 29720522
Cell. 2020 May 28;181(5):997-1003.e9
pubmed: 32359424

Auteurs

Hakon Jonsson (H)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Olafur T Magnusson (OT)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Pall Melsted (P)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.

Jonas Berglund (J)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Arna B Agustsdottir (AB)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Berglind Eiríksdottir (B)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Run Fridriksdottir (R)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Elisabet Eir Garðarsdottir (EE)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Gudmundur Georgsson (G)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Olafia S Gretarsdottir (OS)

Landspitali University Hospital, Reykjavik, Iceland.

Kjartan R Guðmundsson (KR)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Thora Rosa Gunnarsdottir (TR)

Landspitali University Hospital, Reykjavik, Iceland.

Hannes Eggertsson (H)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Arnaldur Gylfason (A)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Hilma Holm (H)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Brynjar O Jensson (BO)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Aslaug Jonasdottir (A)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Frosti Jonsson (F)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Kamilla S Josefsdottir (KS)

Directorate of health, Reykjavik, Iceland.

Marianna Thordardottir (M)

Directorate of health, Reykjavik, Iceland.

Karl G Kristinsson (KG)

Landspitali University Hospital, Reykjavik, Iceland.

Þórður Kristjánsson (Þ)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Droplaug N Magnusdottir (DN)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Louise le Roux (LL)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Jona Saemundsdottir (J)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Asgeir Sigurdsson (A)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Gudrun Sigmundsdottir (G)

Directorate of health, Reykjavik, Iceland.

Gardar Sveinbjornsson (G)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Solvi Rognvaldsson (S)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Ogmundur Eiriksson (O)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Magnus Karl Magnusson (MK)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Kristin Eva Sveinsdottir (KE)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Maney Sveinsdottir (M)

Landspitali University Hospital, Reykjavik, Iceland.

Emil Aron Thorarensen (EA)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Bjarni Thorbjornsson (B)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Arthur Löve (A)

Landspitali University Hospital, Reykjavik, Iceland.

Gudmundur L Norddahl (GL)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Ingileif Jonsdottir (I)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Landspitali University Hospital, Reykjavik, Iceland.

Patrick Sulem (P)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Gisli Masson (G)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.

Alma Moller (A)

Directorate of health, Reykjavik, Iceland.

Thorolfur Gudnason (T)

Directorate of health, Reykjavik, Iceland.

Mar Kristjansson (M)

Landspitali University Hospital, Reykjavik, Iceland.

Agnar Helgason (A)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Department of Anthropology, University of Iceland, Reykjavik, Iceland.

Daniel F Gudbjartsson (DF)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.

Unnur Thorsteinsdottir (U)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland.
Landspitali University Hospital, Reykjavik, Iceland.

Kari Stefansson (K)

deCODE genetics/Amgen, Inc., Reykjavik, Iceland. kstefans@decode.is.
Landspitali University Hospital, Reykjavik, Iceland. kstefans@decode.is.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH